` FGEN (FibroGen Inc) vs S&P 500 Comparison - Alpha Spread

FGEN
vs
S&P 500

Over the past 12 months, FGEN has underperformed S&P 500, delivering a return of -76% compared to the S&P 500's +13% growth.

Stocks Performance
FGEN vs S&P 500

Loading
FGEN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
FGEN vs S&P 500

Loading
FGEN
S&P 500
Difference
www.alphaspread.com

Performance By Year
FGEN vs S&P 500

Loading
FGEN
S&P 500
Add Stock

Competitors Performance
FibroGen Inc vs Peers

S&P 500
FGEN
ABBV
AMGN
GILD
VRTX
Add Stock

FibroGen Inc
Glance View

Market Cap
30.9m USD
Industry
Biotechnology

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 566 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. The firm is also enrolling patients in its two Phase III trials of pamrevlumab patients.

FGEN Intrinsic Value
29.39 USD
Undervaluation 74%
Intrinsic Value
Price
Back to Top